These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9555861)

  • 1. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants.
    Margaglione M; Cappucci G; d'Addedda M; Colaizzo D; Giuliani N; Vecchione G; Mascolo G; Grandone E; Di Minno G
    Arterioscler Thromb Vasc Biol; 1998 Apr; 18(4):562-7. PubMed ID: 9555861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiontensin converting enzyme (ACE) genes.
    Margaglione M; Grandone E; Vecchione G; Cappucci G; Giuliani N; Colaizzo D; Celentano E; Panico S; Di Minno G
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):2082-7. PubMed ID: 9351375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia].
    Jastrzebska M; Widecka K; Ciechanowicz A; Goracy I; Wesołowska T; Torbus-Lisiecka B; Foltyńska-Nowakowska A; Naruszewicz M
    Pol Arch Med Wewn; 2005 Jan; 113(1):7-20. PubMed ID: 16130596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin converting enzyme insertion/deletion polymorphism is associated with plasma antigen levels of plasminogen activator inhibitor-1 in healthy Japanese population.
    Matsubara Y; Hayakawa T; Tsuda T; Takeshita E; Watanabe G; Murata M; Watanabe K; Ikeda Y
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):115-20. PubMed ID: 10759003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
    Matsubara Y; Murata M; Isshiki I; Watanabe R; Zama T; Watanabe G; Watanabe K; Ikeda Y
    Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome.
    Sun L; Lv H; Wei W; Zhang D; Guan Y
    J Endocrinol Invest; 2010 Feb; 33(2):77-82. PubMed ID: 19636212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia].
    Nowakowska A
    Ann Acad Med Stetin; 2005; 51(1):95-105. PubMed ID: 16496609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor-1 and angiotensin I converting enzyme gene polymorphism in patients with hypertension.
    Jeng JR; Harn HJ; Yueh KC; Jeng CY; Shieh SM
    Am J Hypertens; 1998 Feb; 11(2):235-9. PubMed ID: 9524054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-1-converting enzyme (ACE) gene polymorphism, plasma ACE levels, and their association with the metabolic syndrome and electrocardiographic coronary artery disease in Pima Indians.
    Nagi DK; Foy CA; Mohamed-Ali V; Yudkin JS; Grant PJ; Knowler WC
    Metabolism; 1998 May; 47(5):622-6. PubMed ID: 9591757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1.
    Kim DK; Kim JW; Kim S; Gwon HC; Ryu JC; Huh JE; Choo JA; Choi Y; Rhee CH; Lee WR
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3242-7. PubMed ID: 9409318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients.
    Prisco D; Fatini C; Battaglini B; Gensini F; Fedi S; Falai M; Chioccioli M; Gori AM; Margheri M; Gensini GF
    Int J Clin Lab Res; 2000; 30(4):179-85. PubMed ID: 11289708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between plasma t-PA and PAI-1 levels is dependent on epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms.
    Moore JH; Smolkin ME; Lamb JM; Brown NJ; Vaughan DE
    Clin Genet; 2002 Jul; 62(1):53-9. PubMed ID: 12123488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of PAI-1 gene promoter 4g/5g polymorphism with plasma PAI-1 activity in Chinese patients with and without hypertension.
    Jeng JR
    Am J Hypertens; 2003 Apr; 16(4):290-6. PubMed ID: 12670745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy1.
    Kimura H; Gejyo F; Suzuki Y; Suzuki S; Miyazaki R; Arakawa M
    Kidney Int; 1998 Nov; 54(5):1659-69. PubMed ID: 9844142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactive effect of PAI-1 4G/5G genotype and salt intake on PAI-1 antigen.
    Brown NJ; Murphey LJ; Srikuma N; Koschachuhanan N; Williams GH; Vaughan DE
    Arterioscler Thromb Vasc Biol; 2001 Jun; 21(6):1071-7. PubMed ID: 11397722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms.
    Jastrzebskal M; Widecka K; Naruszewicz M; Ciechanowicz A; Janczak-Bazan A; Foltynska A; Goracy I; Chetstowski K; Wesotowska T
    Nutr Metab Cardiovasc Dis; 2004 Oct; 14(5):259-69. PubMed ID: 15673060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women.
    Brown NJ; Abbas A; Byrne D; Schoenhard JA; Vaughan DE
    Circulation; 2002 Jan; 105(3):304-9. PubMed ID: 11804984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin I-converting enzyme and plasminogen activator inhibitor-1 gene variants: risk of mortality and fatal cardiovascular disease in an elderly population-based cohort.
    Heijmans BT; Westendorp RG; Knook DL; Kluft C; Slagboom PE
    J Am Coll Cardiol; 1999 Oct; 34(4):1176-83. PubMed ID: 10520809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
    Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
    Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
    Grancha S; Estellés A; Tormo G; Falco C; Gilabert J; España F; Cano A; Segui R; Aznar J
    Thromb Haemost; 1999 Apr; 81(4):516-21. PubMed ID: 10235431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.